Alzheimer’s disease is a devastating age-related neurodegenerative condition with no known cure. Identifying early mechanisms of the disease and approaches to prevent AD are among the most important priorities of global biomedical research.
Dr. Auwerx and colleagues at the Ecole Polytechnique Federale de Lausanne in
Remarking on Dr. Auwerx’s discovery, Dr.
NR is a vitamin discovered by Dr. Brenner and developed by
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary health and wellness consumer products and ingredient technologies that promote healthy longevity. In addition to our consumer product and ingredient technologies units, we also have business units focused on natural product fine chemicals (known as "phytochemicals"), and product regulatory and safety consulting. As a result of our relationships with leading universities and research institutions, we are able to discover and license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. Our consumer product and ingredient portfolio are backed with clinical and scientific research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene; PURENERGY®, a caffeine-pTeroPure® co-crystal; IMMULINA™, a spirulina extract; AnthOrigin®, anthocyanins derived from a domestically-produced, water-extracted purple corn husk, and ChromaDex’s flagship consumer product TRU NIAGEN™, found at truniagen.com. To learn more about ChromaDex, please visit
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended including statements related to results of the study and its significance related to Alzheimer’s disease and the possibilities as a neuroprotectant. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in
ChromaDex Investor Relations Contact:
ChromaDex Public Relations Contact: